

BMJ Open Prevalence and risk factors of persistent cough in patients diagnosed with renal cell carcinoma: a systematic review and meta-analysis

Wendy Smith ¹, Joseph Santiapillai,^{1,2} Marilena Loizidou ¹,
Stuart Mazzone ^{1,3}, Maxine G B Tran ^{1,2}, Hirak K Patra,¹
Muhammad Imran Omar ^{4,5}, Faiz Mumtaz ^{1,2}

To cite: Smith W, Santiapillai J, Loizidou M, *et al.* Prevalence and risk factors of persistent cough in patients diagnosed with renal cell carcinoma: a systematic review and meta-analysis. *BMJ Open* 2025;**15**:e088963. doi:10.1136/bmjopen-2024-088963

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2024-088963>).

Received 20 May 2024

Accepted 14 February 2025



© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

¹University College London, London, UK

²Royal Free London NHS Foundation Trust, London, UK

³University of Melbourne VCCC, Parkville, Victoria, Australia

⁴Academic Urology Unit, University of Aberdeen, Aberdeen, UK

⁵Guidelines Office, European Association of Urology, Arnhem, The Netherlands

Correspondence to

Wendy Smith;
wendy.smith.21@ucl.ac.uk

ABSTRACT

Objectives Cough occurring in patients with renal cell carcinoma (RCC) was first described in 1935 and is a frequently discussed symptom on patient forums. We aimed to systematically review the available evidence to explore the prevalence and risk factors for persistent cough in patients diagnosed with RCC to establish whether cough could be a presenting symptom of RCC.

Design This epidemiological systematic review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement 2020.

Data sources Medline, Embase, Science Citation Index, The Cochrane Library, ClinicalTrials.gov and the WHO trials register were searched without language restrictions until 1 June 2023.

Eligibility criteria for selecting studies We included articles of all study designs reporting cough in patients (18 years or older) with RCC attributed to the disease itself or to treatment.

Data extraction and synthesis Data from included articles was extracted using a preprepared and piloted form, and quality assessment was conducted independently by two authors. The risk of bias was assessed in studies other than case reports or case series using the critical appraisal instrument for studies reporting prevalence data. Narrative techniques were used for data analysis and, where appropriate, meta-analysis using a fixed-effects model was performed.

Results Of 509 studies screened, 105 full-text articles were assessed, with 46 papers subsequently excluded, resulting in 59 analysed in depth. There were 105 patients with RCC reported as having a cough due to the disease itself within 30 case reports and 8 case series. When present, most coughs were described as persistent and dry in nature. The cause of cough was attributed to various aetiologies including pulmonary and endobronchial metastasis and paraneoplastic syndromes. Studies reporting patients with RCC developing a cough because of systemic treatment were heterogeneous. Two studies with 238 patients on temsirolimus and 230 on interferon- α (IFN- α) were suitable for meta-analysis using a fixed-effects model. Patients on temsirolimus were more likely to develop a cough than those on IFN- α (OR 1.95 with a 95% CI of 1.05 to 3.63, overall effect Z=2.12 (p=0.03), I²=0%).

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ A comprehensive literature search (without language restrictions) was performed to identify all the relevant studies.
- ⇒ The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement 2020 was followed.
- ⇒ The narrative synthesis approach enabled the description and tabulation of patient and disease characteristics.
- ⇒ Narrative synthesis was also used to identify the proposed aetiologies of the cough in patients having a cough due to renal cell carcinoma.
- ⇒ Meta-analysis was limited due to the heterogeneity of the studies.

Conclusion Cough can occur in patients with RCC, as part of the disease pathogenesis, as an adverse effect of systemic treatment or due to unrelated causes such as pre-existing conditions (eg, asthma). Further research is required to determine the true prevalence and cause and to assess whether cough could be a presenting symptom for RCC.

PROSPERO registration number CRD42022302962.

INTRODUCTION

In 2020, there were 431 288 cases of kidney cancer diagnosed globally and an estimated 179 368 deaths from kidney cancer.¹ Renal cell carcinoma (RCC) is now the seventh most common cancer in the UK with an estimated lifetime risk of 3% for men and 2% for women.² Of concern, the incidence of RCC has increased 88% (94% in women and 77% in men) since the 1990s and currently there are approximately 13 300 new cases and 4600 RCC deaths annually in the UK alone. The rate of RCC is expected to rise by a further 26% from 2014 to 2035.³ Many RCCs are diagnosed as an ‘incidental finding,’ with almost 60% of RCCs diagnosed on abdominal

imaging used to investigate other conditions.⁴ Only one-third are diagnosed on the basis of the 'classic' symptoms including haematuria, flank pain, a mass in the abdomen and a varicocele. At all stages, RCC may produce hormone-like or cytokine-like substances resulting in paraneoplastic syndromes which could result in hypertension, anaemia, cachexia, weight loss, fever, hypercalcaemia and polycythaemia.⁵ Some of these substances, for example, prostaglandin E₂ (PGE₂), are known to be involved in the cough reflex.⁶ One-third of all RCCs are stage 4 at presentation, spreading to the lungs, brain, bone and liver and so can present with persistent cough, haemoptysis, abnormal liver function tests and bone pain.⁷

Chronic cough (a cough lasting 8 weeks or more) affects approximately 10% of the adult population and is a common reason why patients visit their general practitioner.⁸ A cause for the cough is identified in approximately half of cases (eg, asthma, bronchiectasis, gastro-oesophageal reflux or a side effect of medication).⁹ This means almost half of patients have a chronic cough without an attributed cause.

The recognition of cough occurring in patients with RCC was first described in 1935 by Creevy,¹⁰ but only a few clinicians seeing patients with RCC or cough are aware of this. The aim of this systematic review is to summarise the available evidence about the prevalence of cough in patients (18 years or over) with RCC, either attributed to the disease itself or due to the systemic treatment used in these patients. This may establish whether cough could be a presenting symptom of RCC, which may lead to an earlier diagnosis of RCC in some patients.

METHODS

A systematic review of the literature from primary studies on cough in adult patients (>18 years old) diagnosed with RCC was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 2020.¹¹ The prospective systematic review protocol was registered on PROSPERO (CRD42022302962). The variations from the protocol included the use of Covidence rather than EndNote software to record the electronic searches, remove duplicates and scan titles to remove any irrelevant work; the quality assessment of all included studies was conducted using the relevant Joanna Briggs Institute (JBI) critical appraisal tools and not for cross-sectional studies as in the protocol, and risk of bias was assessed using the critical appraisal instrument for studies reporting prevalence data instead of Quarterly Income Preferred Securities (QUIP).

Search strategies and selection criteria

A comprehensive systematic literature search was conducted to identify all published studies on the prevalence and persistence of cough in patients (>18 years old) with RCC. Any non-English language papers were translated (using Google Translate) and assessed fully for potential inclusion in the review, as appropriate. The

authors did not apply any design restrictions, and all study designs were included (eg, observational/case/cohort studies, non-randomised and randomised controlled trials).

The following electronic databases were searched: Medline, Embase, Science Citation Index, The Cochrane Library, ClinicalTrials.gov and the WHO trials register from their inception to the search date (completed on 1 June 2023), to identify potential studies using a combination of controlled vocabulary and free-text terms (see online supplemental table S1).

Furthermore, the reference lists of the included studies to identify other relevant studies, the 'related search' function in Medline (PubMed) and Embase (OvidSP) and 'citing reference' search (to search for articles that cited the included studies) in Science Citation Index Expanded and Embase (OvidSP) were reviewed.

The titles and abstracts of the publications were screened independently by two review authors (WS and JS) followed by full-text screening and data extraction in the same manner. Any differences were discussed and mutual agreement obtained. The reasons for exclusions were recorded and reported in a PRISMA flow diagram. Where appropriate, the authors of published trials were contacted for further information and unpublished data. The Covidence software was used to record the electronic searches and to screen for duplicates, and the two studies found to be suitable for meta-analysis were uploaded to RevMan.

Data extraction and analysis

Data were extracted using a preprepared and piloted form. If overlap of participants between multiple reports was suspected due to common study authors or centres, the authors were contacted for clarification. Variables extracted included the: *Study characteristics* (authors, year of publication, institution, single vs multicentre, country, language of publication, study period, study design, number of patients enrolled); *patient characteristics* (age, gender, ethnicity, other comorbidities); *tumour characteristics* (size of primary tumour, tumour subtype, stage of disease); *cough characteristics* (nature, duration prior to diagnosis, if cough was thought to develop due to the RCC itself or treatment of RCC and if the cough resolved or persisted following treatment); *interventions* (no treatment, surgery, embolisation, medical treatment including immunotherapy).

The quality assessment of all included studies was conducted using the relevant JBI critical appraisal tools.^{12–14} These have a variable number of questions depending on the type of publication, and these were ranked as yes (Y), no (N), unclear (U) or not applicable (NA) as recorded in online supplemental table S2. Further information was sought from study authors where necessary. No study was excluded based on the quality assessment scores since it provided information on the current level of evidence. The risk of bias was assessed in studies other than case reports or case

series using the critical appraisal instrument for studies reporting prevalence data.¹³ The online supplemental table S3 shows that the studies had overall scores of 7 or more (out of 9).

Narrative techniques were used for data analysis, with summary median and quartiles calculated when appropriate. For the remaining analysis, only studies that had sufficient information to calculate the effect measures were included. Subgroup analysis was performed for the histological subtype, stage of disease (size of the primary tumour and whether metastases were present or not) and the treatment received. A meta-analysis using ORs was performed when the types of participants, risk factor definitions and the outcome definitions were similar across at least two studies. 95% CIs were used for deciding whether the risk factor had prognostic value, and I^2 and χ^2 tests were used for assessing heterogeneity. The I^2 value was interpreted as per the Cochrane Handbook guidance, and in the absence of heterogeneity or if the I^2 value was under 40% the fixed-effects model was preferred.

Patient and public involvement

Patient and public involvement (PPI) representatives from Kidney Cancer UK formed the PPI support group for the study 'Cough in patients with suspected or confirmed kidney cancer' and met every 6 months to review progress and discuss findings. Each meeting was followed by a newsletter, coproduced with the PPI group and disseminated to Kidney Cancer UK.

RESULTS

Study selection

The selection process is presented by the PRISMA diagram (figure 1). Of 509 reports initially identified, 78 were duplicates and were removed. Following title and abstract screening, 322 were identified as irrelevant (eg, on other diseases, such as sarcoidosis or follicular lymphoma, or on quality of life or non-cough aspects of RCC). Of the remaining 109 studies, four papers could not be sourced despite extensive efforts. A total of 105 publications had a comprehensive full-text evaluation, and 46 papers were




Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 flow diagram for study selection.

subsequently excluded at this stage (14 were due to the wrong population, eg, patients with inherited syndromes at risk of developing RCC; 12 due to insufficient detail, eg, description of cough present in 7 of 11 patients with various cancers but no detail if 2 patients with RCC had a cough). Nine papers were from papers describing the same study population (eg, RECORD1 study), seven did not discuss cough as an outcome (eg, article discussing paraneoplastic syndrome but cough not mentioned) and four were overview articles/discussions, focused on the cause of pulmonary manifestations in patients with RCC.

A total of 59 studies met the inclusion criteria.

Cough attributed to RCC itself

There were 38 publications related to cough due to the RCC itself, and these were conducted in the following countries: 9 in the USA, 6 in Japan, 4 in Canada, 4 in India, 3 in the UK, 2 each from China, Germany and Turkey and 1 each from Australia, Egypt, Malaysia, Morocco, Portugal and Singapore (online supplemental table S4 shows an overview of included studies).

Of these, 30 articles were case reports and 8 were case series. There were no systematic reviews or higher level of evidence studies on cough due to RCC itself. Creedy¹⁰ referred to cough occurring in 9 of 92 patients in his case series while Zhang *et al*¹⁵ described 11 of 1326 having a cough at presentation attributed to presumed lung metastases. Doğan *et al*¹⁶ reported 5 of 11 patients with RCC and endobronchial metastasis having a cough. These were retrospective case series and did not indicate whether the review was of consecutive patients and so the prevalence cannot be deduced. Online supplemental table S4 shows the characteristics of the studies included in this section.

Online supplemental table S5 shows that, in some papers, the age and sex of the patients were not provided. Of the publications describing the age, the range was from late 30s to late 80s, and there was a predominance of male patients (where sex is reported) as would be expected, since RCC has a male predominance.

The nature and duration of cough prior to diagnosis of RCC

Table 1 shows information from 16 papers describing the nature and duration of cough prior to presentation and diagnosis of RCC in 28 patients, where 16 were men, 11 were women and 1 where gender was not stated. The age range was from mid-20s to mid-80s. Nearly all describe the cough as being persistent and dry. Sullivan described a female in her early 60s who presented with an 8-month history of a cough with 'very little phlegm and just aggravating'. Eventually, it became intractable, occurring 'any time during the day or night, except when I was sleeping'. The cough described has features of cough hypersensitivity since it was worse with exertion, cold air and talking.¹⁷ Tatzel and Sener describe a woman in her late 60s with a 3-month history of 'persistent, gradually worsening cough, which on occasion woke her from sleep'.¹⁸ The duration of the cough prior to the RCC being diagnosed ranged from 'recent onset persistent cough',¹⁹

from 2 weeks²⁰ to over 2 years.²¹ Most had a cough that lasted for 3 months.^{18 22–25}

Cough attributed to the treatment of RCC

The 22 publications reporting cough related to treatment of RCC were from the following countries: 6 from the USA, 4 from multiple nations, 3 from Japan, 2 from Spain and 1 each from Canada, Croatia, Germany, Italy, Israel, Serbia and the UK as shown in online supplemental table S6.

There were five case reports, seven case series, four non-randomised experimental studies and six randomised controlled trials (online supplemental table 6). Table 2 indicates that the study size varied from 1 to 903. One publication with 86 participants did not indicate the age of the patients,²⁶ and another study did not indicate the male to female proportion in the 60 participants.²⁷ Excluding these studies in the subgroup analysis for age and sex, respectively, it was apparent that the age range was from late teens to late 80s with 73% male participants (2236 male, 811 female). The significant male preponderance reflects that the incidence of RCC is higher in men than women.

These studies were not designed to determine the prevalence of cough, but cough was mentioned to be present or absent in the participants. Overall, the incidence of cough in patients receiving systemic treatments for RCC (excluding Bukowski *et al*, who only provided the SE²⁸ and Esteban-González *et al* who described the presence of cough in terms of treatment cycles rather than patients²⁹) was 13.48% (262 of 1943 participants). Systemic treatments included the use of 2'-deoxy-5-fluorouridine-infusion (one report), inhaled interleukin 2 (three reports), sorafenib (two reports), sunitinib (two reports), temsirolimus (three reports), interferon-α (IFN-α) (two reports), everolimus (six reports) and nivolumab (four reports) and in one paper each on the use of apitolisib, axitinib, ipilimumab, tivozanib, pazopanib and, most recently, pembrolizumab. This reflects the recent development of new systemic and immunotherapy agents.

Subgroup analysis

Data on the subtype of RCC

Information regarding the diagnosis of clear cell, papillary or chromophobe RCC was limited since most of the studies did not specify the subtype of RCC. Of the 105 patients who developed a cough due to the disease itself, only 17 patients were confirmed as having clear cell type of RCC,^{18 23 25 30–36} 3 with papillary RCC^{37–39} and 2 with non-clear cell renal cell carcinoma (ccRCC).^{40 41}

Data on the size of the primary tumour

Data on the size of the primary tumour are documented in online supplemental table S5. The size was not available for 71 of 105 patients with cough at presentation (2 of these patients had excision of the primary tumour 5 years and 32 years previously).^{42 43} Data were present for 3 patients with T1a,^{25 34} 10 with T1b,^{17 19 23 25 32 41} 6 with

Table 1 The nature and duration of cough prior to diagnosis of RCC with the corresponding patient and disease characteristics

Study ID	Age of patient	Sex of patient	Description of cough	Duration of cough prior to diagnosis	Diagnosis
Alsamman ¹⁹	Late 60s	Male	Persistent cough	Recent onset	4.3 cm tumour in the left kidney with no metastasis
Clark ²⁰	Early 80s	Male	Non-productive	2 weeks	Right kidney mass and thrombus in the right atrium
Custódio ²³	Late 40s	Male	Not stated	3 months	RCC kidney and adenocarcinoma lung
Estfan ²²	Mid-20s	Female	Persistent cough	3 months	RCC kidney and lung metastasis
Giffen ²⁵	Early 70s	Male	Persistent cough	3 months	Right kidney mass
Giffen ²⁵	Mid-50s	Female	Dry, persistent cough	6 months	Not stated
Giffen ²⁵	Mid-50s	Female	Not stated	3 months	Left kidney mass
Giffen ²⁵	Late 70s	Male	Persistent cough	Not stated	Right kidney mass
Giffen ²⁵	Late 70s	Male	Persistent cough	Not stated	Left kidney mass
Giffen ²⁵	Late 60s	Female	Persistent cough	Not stated	Left kidney mass
Giffen ²⁵	Mid-50s	Male	Dry, persistent cough	Not stated	Right kidney mass
Giffen ²⁵	Early 70s	Female	Dry, persistent cough	Not stated	Bilateral kidney masses
Hagen ²¹	Late 30s	Male	Dry, persistent cough	2 years	Right RCC no metastasis
Li Fraire ⁵²	Mid-40s	Male	Persistent cough	Not stated	RCC kidney and cardiac metastasis
Mazouz ³⁴	Mid-50s	Male	Dry cough	6 months	Right kidney and second primary of non-small cell carcinoma of the lung
Mukherjee ⁵¹	Mid-60s	Female	Persistent cough	2 months	Left RCC and endobronchial metastases
Okubo ³¹	Mid-60s	Female	Obstinate cough	1 year	Left kidney mass, no metastasis
Patel ²⁴	Not stated	5 Males and 1 female	Not stated	3 months to a year	Five ccRCC, one unclassified, four no metastasis; two with metastasis
Sharma ⁴⁵	Mid-50s	Male	Dry cough	6 months	Left kidney RCC no metastasis
Singh ⁴⁴	Mid-80s	Female	Dry, persistent cough	2 months	Left kidney RCC metastasis to regional lymph nodes
Sullivan ¹⁷	Early 60s	Female	Dry, persistent, except when sleeping	8 months	Right kidney ccRCC metastasis to lymph nodes and spine (L4)
Tatzel ¹⁸	Late 60s	Female	'Persistent, gradually worsening cough, which on occasion woke her from sleep'	3 months	Right kidney ccRCC no metastasis
Yang ⁴⁰	Late 20s	Male	Dry cough	4 months	Left kidney medullary carcinoma. Lung and liver metastases

ccRCC, clear cell renal cell carcinoma.

T2a,^{18 24 25 40 44} 3 with T2b,^{24 35 45} 8 with T3^{24 31 36 38 46 47} and 4 with T4 tumours.^{24 33 37 48} This suggests that cough can occur in some patients with small T1 tumours, when the cancer is still at an early stage.

Data on the presence or absence of metastases in patients with RCC who had a cough at presentation

Of 105 patients who had a cough at presentation, 16 patients had no metastases identified, 86 patients were identified as having metastases, 2 had a synchronous lung primary^{23 34} and in 1 study, the presence or absence of metastases was not discussed.²⁰

Metastatic disease was reported in 86 patients, and it is apparent that RCC can metastasise to a number of different sites within the body. 26 patients had pulmonary metastases,^{10 15 32 35 36 41 46 48} 1 of whom also had liver

metastasis.⁴⁰ 12 had endobronchial metastasis,^{16 42 49–51} 3 patients had cardiac metastases,^{20 37 52} 2 had spinal involvement^{17 24} and 1 patient each had lymphangitis carcinomatosa,⁴⁷ metastasis in the larynx,⁵³ femur²⁴ and pleura⁴³ and pleura with brain metastasis.⁵⁴ The site of metastatic disease was not reported in 37 patients.

Impact of metastases on resolution of cough

Of the 28 patients identified as having resolution of their cough, 12 had metastasis present, 15 did not, and in 1 patient it was not stated whether metastasis was present or not.

86 patients were identified as having metastases; however, there was insufficient detail on the 31 patients in the study by Tiwari *et al*, so these patients were excluded in the analysis.⁵⁵ Of the remaining 55 patients identified

Table 2 Patient characteristics and intervention in studies included in the review on cough attributed to treatment						
Study identification	Intervention	Number of patients	Age*	Number M/F	Cough present	P value
Huland ⁶⁷	Inhaled interleukin 2	15	Early 40s to early 70s	10 M 5 F	13 of 15	–
Wong ⁶⁸	2'-Deoxy-5-fluorouridine infusion	3	Late 40s, early 60s, mid-70s	2 M 1 F	2	–
Merimsky ⁶⁹	Inhaled interleukin 2	40	66.5 (range mid-40s to late 80s)	30 M 10 F	8	–
Bukowski ²⁸	Sorafenib versus placebo	451 versus 452	59.1 (range late teens to mid-80s) versus 58.4 (range late 20s to mid-80s)	315 M 136 F versus 340 M 112 F	SE 3.36 versus 3.11	<0.0001 Favours sorafenib
Esteban-Gonzalez ²⁹	Inhaled interleukin 2	51	62 (range early 30s to early 80s)	41 M 10 F	399 of 1000 treatment cycles	–
Hudes ⁶⁵	Temsirolimus versus IFN-α versus temsirolimus and IFN-α	208 versus 200 versus 210	58 (range early 30s to early 80s) versus 60 (range early 20s to mid-80s) versus 59 (range early 30s to early 80s)	139 M 70 F versus 148 M 59 F versus 145 M 65 F	126 of 208 versus 14 of 200 versus 23/208	–
Motzer ⁶⁰	Everolimus versus placebo	277 versus 139	61 (range late 20s to mid-80s) versus 60 (range late 20s to late 70s)	216 M 61 F versus 106 M 33 F	30 of 277 versus 16 of 137	0.398
Muriel ⁷⁰	CK (IFN-α) ± chemotherapy versus tyrosine kinase inhibitors (TKIs) (sunitinib and sorafenib) alone versus CK and TKI	46 versus 28 versus 20	60 (range early 30s to late 70s) versus 60 (range early 40s to late 70s) versus 62 (range early 40s to mid-70s)	39 M 7 F 21 M 7 F versus 16 M 4 F	CK 19/66 versus TKI 0/48	–
Cauley ²⁶	Everolimus	86	Not stated	60 M 26 F	14/24 who developed EAP	–
Ryan ⁷¹	Everolimus	19	65 (range early 50s to late 70s)	16 M 3 F	Seven of 19	–
Saito ⁷²	Everolimus	1	Mid-70s	1 F	1	–
Atkinson ⁷³	Temsirolimus versus everolimus versus both	310	61	220 M 90 F	26 of 310	–
Kust ⁷⁴	Sunitinib	1	Late 50s	1 M	1	–
Levakov ²⁷	Temsirolimus versus IFN-α	30 versus 30	Median age not stated (range late teens to mid-60s)	Not stated	6/30 versus 3/30	0.143
Powles ⁶¹	Apitolisib versus everolimus	42 versus 43	61 (range mid-40s to mid-70s) versus 62 (range late 30s to early 90s)	33 M 9 F versus 31 M 12 F	4/42 versus 11/43	0.03
Escudier ⁶²	Nivolumab initial treatment versus treatment despite disease progression	153 versus 163	62 (range late 20s to mid-80s) versus 63 (range early 20s to mid-80s)	116 M 37 F versus 128 M 35 F	10/153 versus 11/163	0.469

Continued

Table 2 Continued

Study identification	Intervention	Number of patients	Age*	Number M/F	Cough present	OR	P value
Gutierrez ⁷⁵	Nivolumab	8	71 (range late 60s to mid-70s)	6 M 2 F	4 of 8	-	-
Mendiola ⁵⁶	Nivolumab	1	Late 50s	1 M	1	-	-
Restuccia ⁷⁶	Tivozanib	17	70 (range late 40s to early 80s)	13 M 4 F	1	-	-
Harada ⁷⁷	Pazopanib	1	Mid-70s	1 M	1	-	-
Watanabe ⁷⁸	Nivolumab and ipilimumab	1	Late 70s	1 F	1	-	-
Atkins ⁷⁹	Axitinib and pembrolizumab	52	63	41 M 11 F	25 but 8 to treatment	-	-

*To prevent patient identification, specific ages have been replaced by 'early', 'mid', 'late', '20s', '30s'. Absolute values of median age are included where available.
†The patients analysed did not include those who underwent randomisation but did not receive treatment.²⁹
EAP, everolimus-associated pneumonitis; F, female; IFN- α , interferon α ; M, male.

as having metastases, 12 had resolution of their cough. (In 31 patients, the outcome was not stated, 9 patients died and the cough persisted in 3 patients). Of the 12 patients with metastases whose cough resolved, treatment included cytoreductive nephrectomy in 5²⁴ and cytoreductive nephrectomy combined with other treatments in 6 patients.^{17 22 24 46 49} Despite the presence of known metastases, the cough resolved/reduced soon after the nephrectomy in all 11 patients suggesting the primary tumour is responsible in some way for the cough. The twelfth participant's cough resolved after treatment with only sunitinib.⁴³

The development of cough from the treatment

Some systemic treatments for RCC, including mammalian target of rapamycin (mTOR) inhibitors, tyrosine kinase inhibitors (TKIs) and antiprogrammed death-1 checkpoint inhibitors (ICIs) can result in the development of non-infectious pneumonitis (NIP) in anything up to 45% of patients depending on the class, dose and duration of medication.⁵⁶⁻⁵⁹ Patients with grade 1 NIP are asymptomatic, but cough/dyspnoea is present with grades 2-4 NIP. Only patients identified as having a cough were included in this review. Cough has been reported in 60.7 and 72.2% in patients on everolimus and temsirolimus, respectively;⁵⁹ however, Levakov *et al* stated none of their patients with a cough had NIP.²⁷

Only four studies were suitable for OR and p values to be calculated. Motzer *et al* did not find cough to be found significantly more or less frequently in patients taking everolimus compared with placebo (p=0.398);⁶⁰ however, Powles *et al* found cough in significantly more patients on everolimus compared with those on apitolisib (p=0.03).⁶¹ Bukowski *et al* identified that patients treated with sorafenib rather than placebo were less likely to cough (p<0.0001).²⁸

Escudier found that in patients who continued with nivolumab despite disease progression, there was no significant change (p=0.469) in the presence of cough.⁶²

Meta-analysis of studies on patients on temsirolimus and IFN- α developing a cough

Formal meta-analysis was performed on only two studies where the same intervention was measured. It reported the OR of developing a cough in 238 patients on temsirolimus compared with 230 patients on IFN- α , and the outcome is shown in figure 2. The forest plot favours treatment with IFN- α , that is, patients on IFN- α are less likely to have a cough (an adverse event) than those on temsirolimus. There is no heterogeneity (I²=0%) and so a fixed-effects model was used. The p value of 0.03 indicates that the difference between the two groups is statistically significant.

DISCUSSION

This systematic review has explored the current evidence summarising the prevalence of cough in patients with

Fixed-effects model:




Figure 2 Cough in patients on temsirolimus versus IFN- α . IFN- α interferon- α ; IV, intravenous.

RCC due to the disease itself. No studies or publications were found to directly answer this question. Creedy¹⁰ referred to cough occurring in 9 of 92 patients in his case series, Zhang *et al*¹⁵ described 11 of 1326 patients having a cough at presentation and Doğan *et al*¹⁶ reported 5 of 11 patients with RCC and endobronchial metastasis had a cough.

This systematic review found 105 patients who developed a cough attributed to RCC. The majority had metastases (86/105). The cause of the cough was mainly attributed to the presence of metastases principally in the lung, endobronchial and intracardiac, or as a symptom manifestation of a paraneoplastic syndrome. RCC was found in all 28 patients (described in table 1) as an incidental finding on a chest CT performed to investigate their cough. These studies report the cough having been present from 2 weeks to over a year before a diagnosis of RCC was made. The cough appears to be a persistent dry cough, with some reporting exacerbations with exertion, cold air and speech, features suggestive of cough hypersensitivity. The resolution of cough following treatment was reported in 28 patients. Interestingly, in 11 patients with metastases, the cough resolved following cytoreductive nephrectomy, suggesting a possible tumour burden effect. Though some renal tumours were large (9.1 cm and 10 cm),^{18 25} other tumours were small (3.8 cm)²⁵ or located in the lower pole of the kidney,³⁰ suggesting another cause of cough other than through direct diaphragmatic irritation. Embolisation has also been reported to reduce cough, and in these patients the bulk of the tumour remains.³⁸ The hypersensitive nature of the cough described is supportive that cough neural pathways are more sensitive to stimuli, and mediators of hypersensitivity could arise from the primary tumour. Possible mediators include prostaglandins, such as PGE₂, which have been found in RCCs⁶³ or interleukin 6.⁶⁴ Further research is required to confirm a paraneoplastic cause.

Unfortunately, there is insufficient data to determine whether cough is associated with particular histological subtypes of RCC. The limited studies only included patients with ccRCC and papillary RCC, and a focused prevalence study is required to investigate this further.

This systematic review has shown that overall, 13.48% (262 of 1943 participants) reported a cough in patients

receiving medical treatment of their RCC. These studies were not set up specifically to find the prevalence of cough, but cough was mentioned to be present or not in the participants. Some studies, however, indicate that treatments, for example, temsirolimus and IFN- α ^{27 65} may be responsible for a cough developing in patients with RCC. Cough may develop in patients on mTORs, ICI and TKIs if NIP (grades 2–4) occurs.²⁷

Overall, there were limited studies suitable for meta-analysis. The forest plot in figure 2 showed that patients on IFN- α were less likely to have a cough than patients treated with temsirolimus. The cough may develop because of the RCC itself, either from the primary tumour or through metastatic spread. Bukowski *et al* showed that sorafenib-treated patients reported significantly fewer symptoms versus placebo, including cough ($p < 0.0001$).²⁸

The heterogeneity and nature of the studies identified in this review resulted in some necessary deviations from the protocol registered on PROSPERO (CRD42022302962). We used the relevant JBI critical appraisal tools and not cross-sectional studies as in the protocol, and risk of bias was assessed using the critical appraisal instrument for studies reporting prevalence data instead of QUIP. The lack of awareness of a possible association between cough and kidney cancer is likely to result in under-reporting of this relationship in the literature.

Conclusion

This systematic review suggests that there may be an association of cough in patients with RCC, which typically resolves following treatment of the primary tumour. There is insufficient evidence to determine the prevalence of cough in patients due to the RCC itself, and a prospective study to evaluate this is currently ongoing.⁶⁶ Should a causal link be determined, the utility of cough as a potential symptom of kidney cancer can be further explored, improving diagnosis and enabling earlier treatment for kidney cancer.

X Wendy Smith @wendysmithent and Muhammad Imran Omar @drimranomar

Acknowledgements We acknowledge the contribution of Professor Kurinchi Gurusamy for input to the design of the systematic review published on PROSPERO registration number CRD42022302962.

Contributors Study concept and design: WS. Acquisition of data: WS and JS. Analysis and interpretation of data: WS, JS, MIO and MGBT. Original draft: WS. Writing—reviewing and editing: WS, JS, HKP, ML, MIO, FM, SM and MGBT. Study supervision: MIO and MGBT. All authors had full access to the data and take responsibility for the integrity of the data and accuracy of the analysis. WS is guarantor. All authors read and approved the final manuscript.

Funding This work was supported with awards from The Kidney Cancer Research Foundation (Award 177365) and ENT UK Research Foundation (ENTUKFRG014).

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Wendy Smith <http://orcid.org/0000-0002-7674-2110>

Marilena Loizidou <http://orcid.org/0000-0002-0900-9795>

Stuart Mazzone <http://orcid.org/0000-0001-5270-1333>

Maxine G B Tran <http://orcid.org/0000-0002-6043-4433>

Muhammad Imran Omar <http://orcid.org/0000-0002-1597-3126>

Faiz Mumtaz <http://orcid.org/0000-0002-0211-3936>

REFERENCES

- Sung H, Ferlay J, Siegel RL, *et al*. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209–49.
- Cancer Research UK, Available: <https://www.cancerresearchuk.org/about-cancer/kidney-cancer/about>
- Renal cancer management. *Pharm J* 2022.
- Vasudev NS, Wilson M, Stewart GD, *et al*. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. *BMJ Open* 2020;10:e035938.
- Young M, Jackson-Spence F, Beltran L, *et al*. Renal cell carcinoma. *Lancet* 2024;404:476–91.
- Riccio MM, Myers AC, Udem BJ. Immunomodulation of afferent neurons in guinea-pig isolated airway. *J Physiol* 1996;491:499–509.
- Kidney Cancer Care, Available: <https://www.kcuk.org.uk/kidneycancer/symptoms-of-kidney-cancer/>
- Song W-J, Chang Y-S, Faruqi S, *et al*. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. *Eur Respir J* 2015;45:1479–81.
- Gibson P, Wang G, McGarvey L. Correction to reference in: Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report. *Chest* 2016;149:1353.
- Creevy CD. Confusing clinical manifestations of malignant renal neoplasms. *Arch Intern Med* 1935;55:895.
- Page MJ, McKenzie JE, Bossuyt PM, *et al*. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.
- Munn Z, Barker TH, Moola S, *et al*. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. *JBI Evid Synth* 2020;18:2127–33.
- Munn Z, Moola S, Lisy K, *et al*. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc* 2015;13:147–53.
- Barker TH, Stone JC, Sears K, *et al*. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. *JBI Evid Synth* 2023;21:494–506.
- Zhang Y, Yu H, Li H. Survival analysis of surgically treated renal cell carcinoma: a single Chinese medical center experience from 2002 to 2012. *Int Urol Nephrol* 2015;47:1327–33.
- Doğan D, Turan D, Özgül MA, *et al*. The role of interventional pulmonology in endobronchial metastasis of renal cell carcinoma. *Tuberk Toraks* 2019;67:211–8.
- Sullivan S. Paraneoplastic Cough and Renal Cell Carcinoma. *Can Respir J* 2016;2016:5938536.
- Tatzel S, Sener A. Persistent dry cough: an unusual presentation of renal cell carcinoma. *CMAJ* 2014;186:136.
- Alsamman MA, Draper D. Nonmetastatic renal cell carcinoma presenting with persistent cough: Case report with literature review. *Avicenna J Med* 2019;9:160–3.
- Clark J, Olsen K. To PE or not to PE: Extensive tumor thrombus mimicking pulmonary embolism in a patient with a renal mass. *J Gen Intern Med* 2020;35.
- Hagen N, Temple WJ, Baker T. Cough as a systemic manifestation of cancer. *J Pain Symptom Manage* 1994;9:3–4.
- Estfan B, Walsh D. The cough from hell: diazepam for intractable cough in a patient with renal cell carcinoma. *J Pain Symptom Manage* 2008;36:553–8.
- Custódio S, Joaquim A, Peixoto V, *et al*. Metastatic Renal Cell Carcinoma: The Importance of Immunohistochemistry in Differential Diagnosis. *Case Rep Oncol* 2012;5:30–4.
- Patel VR, Morganstern BA, Kavoussi LR. Persistent cough as a paraneoplastic presenting symptom in six patients with renal cell carcinoma. *Asian J Urol* 2017;4:10–3.
- Giffen ZC, Flynn RM, Mostafa HI, *et al*. Cough as Presenting Symptom of Renal Cell Carcinoma. *SN Compr Clin Med* 2021;3:221–6.
- Cauley DH, Atkinson BJ, Corn PG, *et al*. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. *JCO* 2011;29:332.
- Levakov I, Vojinovic S, Marusic G, *et al*. Safety profile of temsirolimus in patients with metastatic renal cell carcinoma. *J BUON* 2016;21:1442–8.
- Bukowski R, Cella D, Gondek K, *et al*. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. *Am J Clin Oncol* 2007;30:220–7.
- Esteban-González E, Carballido J, Navas V, *et al*. Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. *Anticancer Drugs* 2007;18:291–6.
- Roberts L, Wood G, Whitby M, *et al*. An unusual case of chronic cough. *Aust N Z J Med* 1991;21:780.
- Okubo Y, Yonese J, Kawakami S, *et al*. Obstinate cough as a sole presenting symptom of non-metastatic renal cell carcinoma. *Int J Urol* 2007;14:854–5.
- Hisamatsu H, Yamashita S. Successful cumulative treatment with pre/post-operative interferon-alpha, nephrectomy, and surgical resection of metastasis in advanced renal cell carcinoma: a case report. *Hinyokika Kiyo* 2010;56:155–8.
- Todenhöfer T, Wirths S, von Weyhern CH, *et al*. Severe paraneoplastic hypereosinophilia in metastatic renal cell carcinoma. *BMC Urol* 2012;12:7.
- Mazouz A, Amaadour L, Souaf I, *et al*. Synchronous malignant renal mass in patient with a Lung cancer: case report and literature review. *Pan Afr Med J* 2015;20:22.
- Imai Y, Matsuura T, Hisakane A, *et al*. A Case of Renal Cell Carcinoma Choroidal Metastasis Diagnosed from Vision Disorders. *Hinyokika Kiyo* 2019;65:33–7.
- Izumi K, Iimura Y, Hiruma K, *et al*. Clinical response to sodium glucose co-transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma. *IJU Case Rep* 2019;2:269–71.
- Moser C, Risse N, Langer HJ, *et al*. Cardiac metastasis as cause of therapy-resistant heart failure. *Dtsch Med Wochenschr* 1991;116:1670–4.
- Fujikawa A, Daidoh Y, Taoka Y, *et al*. Immediate improvement of a persistent cough after tumor embolization for renal cell carcinoma—a rare manifestation of paraneoplastic syndrome. *Scand J Urol Nephrol* 2002;36:393–5.

- 39 Floyd MS Jr, Javed S, Pradeep KE, *et al.* Composite oncocytoma and papillary renal cell carcinoma of the kidney treated by partial nephrectomy: a case report. *ScientificWorldJournal* 2011;11:1173–7.
- 40 Yang T, Vintch J. An Unusual Cause of Cough. *Chest* 2016;150:1086A.
- 41 Hasan A, Abozied H, Youssef A, *et al.* A rare case of collecting duct carcinoma with first presentation of respiratory symptoms. *Urol Case Rep* 2020;33:101367.
- 42 Poh M-E, Liam C-K, Pang Y-K, *et al.* Endobronchial metastasis from resected renal cell carcinoma causing total lung collapse. *Respirol Case Rep* 2013;1:26–7.
- 43 Philip A, Jojo A, Keechilat P. Recurrence of renal cell carcinoma after three decades in an octogenarian: Small molecules adding life to years. *J Cancer Res Ther* 2021;17:584–6.
- 44 Singh A, Everest S, Nguyen L, *et al.* Intractable Cough Associated With Renal Cell Carcinoma. *Cureus* 2021;13.
- 45 Sharma MV, Kakkilaya BS, Shekh IA, *et al.* A rare cause for a common symptom. *Breathe (Sheff)* 2016;12:e64–74.
- 46 Kura N, Kojima S, Kakehi R, *et al.* Dilated cardiomyopathy following alpha interferon therapy of renal tumor with pulmonary metastases: a case report. *Hinyokika Kiyo* 1992;38:1051–4.
- 47 Kirk JE, Kumaran M. Lymphangitis carcinomatosa as an unusual presentation of renal cell carcinoma: a case report. *J Med Case Rep* 2008;2:19.
- 48 Poon E, Ong SJ, Chuang XE, *et al.* “Prechronous” metastasis in clear cell renal cell carcinoma: a case report. *J Med Case Rep* 2011;5:181.
- 49 Jariwalla AG, Seaton A, McCormack RJ, *et al.* Intrabronchial metastases from renal carcinoma with recurrent tumour extirpation. *Thorax* 1981;36:179–82.
- 50 Akoglu S, Uçan ES, Celik G, *et al.* Endobronchial metastases from extrathoracic malignancies. *Clin Exp Metastasis* 2005;22:587–91.
- 51 Banerjee J, Mondal M, Banerjee D, *et al.* Renal cell carcinoma manifests primarily as endobronchial mass: An unusual presentation. *Clin Cancer Investig J* 2015;4:237.
- 52 Li Fraine S, Coman D, Durand M, *et al.* Renal Cell Carcinoma With Cardiac Metastases. *World J Oncol* 2021;12:124–6.
- 53 Subramanyam NS, Fendley H, Freeman WH. Coughing up of metastatic tumor as the initial clinical manifestation of renal cell carcinoma. *J Ark Med Soc* 1991;88:86–7.
- 54 Kragel C, Wei S. Renal cell carcinoma metastasizing to solitary fibrous tumor of the pleura: a case report. *J Med Case Rep* 2011;5:248.
- 55 Tiwari P, Kumar L, Singh G, *et al.* Renal Cell Cancer: Clinicopathological Profile and Survival Outcomes. *Indian J Med Paediatr Oncol* 2018;39:23–7.
- 56 Mendiola VL, Kesireddy M, Jana B. Nivolumab-Induced, Late-Onset, Steroid-Sensitive, High-Grade Pneumonitis and Durable Tumor Suppression in Metastatic Renal Cell Carcinoma: A Case Report. *Case Rep Oncol Med* 2019;2019:6759472.
- 57 Albiges L, Chamming's F, Duclos B, *et al.* Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. *Ann Oncol* 2012;23:1943–53.
- 58 Amato R, Stepankiw M. Evaluation of everolimus in renal cell cancer. *Expert Opin Pharmacother* 2013;14:1229–40.
- 59 Cauley DH, Atkinson BJ, Ng CS, *et al.* Everolimus (E) and temsirolimus (T) associated pneumonitis (P) in patients with metastatic renal cell cancer (mRCC): A single-center experience. *JCO* 2012;30:401.
- 60 Motzer RJ, Robbins PB, Powles T, *et al.* Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. *Nat Med* 2020;26:1733–41.
- 61 Powles T, Lackner MR, Oudard S, *et al.* Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. *J Clin Oncol* 2016;34:1660–8.
- 62 Escudier B, Motzer RJ, Sharma P, *et al.* Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. *Eur Urol* 2017;72:368–76.
- 63 Cummings KB, Robertson RP. Prostaglandin: increased production by renal cell carcinoma. *J Urol* 1977;118:720–3.
- 64 Paule B, Belot J, Rudant C, *et al.* The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. *J Clin Pathol* 2000;53:388–90.
- 65 Hudes G, Carducci M, Tomczak P, *et al.* Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. *N Engl J Med* 2007;356:2271–81.
- 66 Smith W, Loizidou M, Mazzone S, *et al.* Protocol for a mixed-method study to assess chronic cough in patients with renal cell carcinoma: the prevalence, impact on quality of life, trigger and potential clinical application of chronic cough as an early screening tool in patients with kidney cancer. *BMJ Open* 2023;13:e074077.
- 67 Huland E, Heinzer H, Huland H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon γ in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. *J Cancer Res Clin Oncol* 1994;120:221–8.
- 68 Wong MK, Bjarnason GA, Hrushesky WJ, *et al.* Steroid-responsive interstitial lung disease in patients receiving 2'-deoxy-5-fluorouridine-Infusion chemotherapy. A report of three cases. *Cancer* 1995;75:2558–64.
- 69 Merimsky O, Gez E, Weitzen R, *et al.* Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2. *Ann Oncol* 2004;15:610–2.
- 70 Muriel C, Esteban E, Corral N, *et al.* Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. *Clin Transl Oncol* 2010;12:562–7.
- 71 Ryan CW, Vuky J, Chan JS, *et al.* A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma. *Invest New Drugs* 2011;29:374–9.
- 72 Saito Y, Nagayama M, Miura Y, *et al.* A Case of Pneumocystis Pneumonia Associated with Everolimus Therapy for Renal Cell Carcinoma. *Jpn J Clin Oncol* 2013;43:559–62.
- 73 Atkinson BJ, Cauley DH, Ng C, *et al.* Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. *BJU Int* 2014;113:376–82.
- 74 Kust D, Kruljac I, Peternac AŠ, *et al.* Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism. *Acta Clin Belg* 2016;71:175–7.
- 75 Baez Gutierrez N, Flores Moreno S, Abdelkader Martin L, *et al.* Effectiveness and safety of nivolumab in elderly patients with renal cell cancer. *Europ J Oncol Pharm* 2018;1:55–6.
- 76 Restuccia S, Randon G, Claps M, *et al.* Safety profile of tivozanib in first-line treatment for advanced renal cell carcinoma (RCC): A realworld retrospective study. *Tumori* 2019;105.
- 77 Harada Y, Kakimoto S, Shimizu T. Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma. *BMJ Case Rep* 2020;13:e235177.
- 78 Watanabe H, Asada K, Shirai T, *et al.* Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab. *Respirol Case Rep* 2020;8:e00638.
- 79 Atkins MB, Plimack ER, Puzanov I, *et al.* Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. *Eur J Cancer* 2021;145:1–10.